HomeComparePLXP vs SBUX

PLXP vs SBUX: Dividend Comparison 2026

PLXP yields 2298.85% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLXP wins by $36577739038.69M in total portfolio value
10 years
PLXP
PLXP
● Live price
2298.85%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36577739038.85M
Annual income
$33,694,466,973,692,370.00
Full PLXP calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — PLXP vs SBUX

📍 PLXP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPLXPSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PLXP + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PLXP pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PLXP
Annual income on $10K today (after 15% tax)
$195,402.30/yr
After 10yr DRIP, annual income (after tax)
$28,640,296,927,638,510.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, PLXP beats the other by $28,640,296,927,582,548.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PLXP + SBUX for your $10,000?

PLXP: 50%SBUX: 50%
100% SBUX50/50100% PLXP
Portfolio after 10yr
$18288869519.50M
Annual income
$16,847,233,486,879,104.00/yr
Blended yield
92.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

PLXP
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Altman Z
-10.3
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PLXP buys
0
SBUX buys
0
No recent congressional trades found for PLXP or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPLXPSBUX
Forward yield2298.85%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$36577739038.85M$157.5K
Annual income after 10y$33,694,466,973,692,370.00$65,840.13
Total dividends collected$36375156338.99M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy

Year-by-year: PLXP vs SBUX ($10,000, DRIP)

YearPLXP PortfolioPLXP Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$240,585$229,885.06$11,107$407.21+$229.5KPLXP
2$5,426,296$5,168,870.07$12,512$626.87+$5.41MPLXP
3$114,761,014$108,954,877.01$14,366$978.69+$114.75MPLXP
4$2,276,338,467$2,153,544,182.26$16,929$1,557.50+$2276.32MPLXP
5$42,357,698,654$39,922,016,494.37$20,658$2,543.80+$42357.68MPLXP
6$739,586,041,815$694,263,304,255.43$26,406$4,302.22+$739586.02MPLXP
7$12,120,492,876,395$11,329,135,811,652.31$35,877$7,622.00+$12120492.84MPLXP
8$186,486,946,005,072$173,518,018,627,329.40$52,741$14,352.64+$186486945.95MPLXP
9$2,694,646,789,868,656$2,495,105,757,643,229.00$85,676$29,243.03+$2694646789.78MPLXP
10$36,577,739,038,851,830$33,694,466,973,692,370.00$157,513$65,840.13+$36577739038.69MPLXP

PLXP vs SBUX: Complete Analysis 2026

PLXPStock

PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.

Full PLXP Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this PLXP vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PLXP vs SCHDPLXP vs JEPIPLXP vs OPLXP vs KOPLXP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.